- Disease: Mpox
- Study type: Randomised Clinical Trial, Prevention
- Study type descriptors: Interventional
- Objective: To assess the reactogenicity, safety, tolerability and immunogenicity of the multivalent vaccine candidate BNT166a in healthy participants with and without prior history of smallpox vaccination
- Number of participants enrolled: Enrollment data not available
- Study enrolling from to
Sites (9)
- Wythenshawe Hospital (Manchester, United Kingdom)
- Alliance for Multispecialty Research (United States) (Knoxville, TN, United States)
- St Thomas’ Hospital (London, United Kingdom)
- Royal Surrey NHS Foundation Trust (Guildford, United Kingdom)
- University Hospital Southampton NHS Foundation Trust (Southampton, United Kingdom)
- Addenbrooke’s Hospital (Cambridge, United Kingdom)
- California Research Foundation (San Diego, CA, United States)
- University of Washington (Seattle, WA, United States)
- AMR Clinical Kansas City (Kansas City, MO, United States)
Study Data
- Adults (18-64 years)
- General population
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Vaccination
- BNT166a
External Links
Other information
Funders/Sponsors:
- BioNTech SE
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to